Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 1 to 20 of 128

1.

Health-related quality of life issues in urinary urge incontinence.

Badía X, Ibarz R.

Expert Rev Pharmacoecon Outcomes Res. 2002 Aug;2(4):357-65. doi: 10.1586/14737167.2.4.357.

PMID:
19807442
2.

Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.

Chapple C, Herschorn S, Abrams P, Sun F, Brodsky M, Guan Z.

Eur Urol. 2009 Sep;56(3):534-41. doi: 10.1016/j.eururo.2008.11.026. Epub 2008 Nov 24.

PMID:
19070418
3.

Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women.

Rogers R, Bachmann G, Jumadilova Z, Sun F, Morrow JD, Guan Z, Bavendam T.

Int Urogynecol J Pelvic Floor Dysfunct. 2008 Nov;19(11):1551-7. doi: 10.1007/s00192-008-0688-6. Epub 2008 Aug 7.

PMID:
18685795
4.

Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder.

Rovner ES, Rackley R, Nitti VW, Wang JT, Guan Z; 037 Study Group.

Urology. 2008 Sep;72(3):488-93. doi: 10.1016/j.urology.2008.05.019. Epub 2008 Jul 17.

PMID:
18639327
5.

Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms.

Rovner ES, Kreder K, Sussman DO, Kaplan SA, Carlsson M, Bavendam T, Guan Z.

J Urol. 2008 Sep;180(3):1034-41. doi: 10.1016/j.juro.2008.05.050. Epub 2008 Jul 17.

PMID:
18639297
6.

Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size.

Roehrborn CG, Kaplan SA, Jones JS, Wang JT, Bavendam T, Guan Z.

Eur Urol. 2009 Feb;55(2):472-9. doi: 10.1016/j.eururo.2008.06.032. Epub 2008 Jun 17.

PMID:
18583022
7.

Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.

Kaplan SA, Roehrborn CG, Chancellor M, Carlsson M, Bavendam T, Guan Z.

BJU Int. 2008 Nov;102(9):1133-9. doi: 10.1111/j.1464-410X.2008.07761.x. Epub 2008 May 26.

8.

Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study.

Dmochowski RR, Sand PK, Zinner NR, Staskin DR.

Urology. 2008 Mar;71(3):449-54. doi: 10.1016/j.urology.2007.11.008.

PMID:
18342185
9.

Clinical relevance of health-related quality of life outcomes with darifenacin.

Abrams P, Kelleher C, Huels J, Quebe-Fehling E, Omar MA, Steel M.

BJU Int. 2008 Jul;102(2):208-13. doi: 10.1111/j.1464-410X.2008.07523.x. Epub 2008 Jul 1.

10.

Systematic review: randomized, controlled trials of nonsurgical treatments for urinary incontinence in women.

Shamliyan TA, Kane RL, Wyman J, Wilt TJ.

Ann Intern Med. 2008 Mar 18;148(6):459-73. Epub 2008 Feb 11. Review. Erratum in: Ann Intern Med. 2011 Dec 6;155(11):796.

PMID:
18268288
11.

Solifenacin treatment for overactive bladder in Hispanic patients: patient-reported symptom bother and quality of life outcomes from the VESIcare Open-Label Trial.

Capo' JP Jr, Laramée C, Lucente V, Fakhoury A, Forero-Schwanhaeuser S.

Int J Clin Pract. 2008 Jan;62(1):39-46. Epub 2007 Nov 23.

PMID:
18036164
12.

Long-term darifenacin treatment for overactive bladder in patients aged 65 years and older: analysis of results from a 2-year, open-label extension study.

Hill S, Elhilali M, Millard RJ, Dwyer PL, Lheritier K, Kawakami FT, Steel M.

Curr Med Res Opin. 2007 Nov;23(11):2697-704.

PMID:
17892634
13.

Darifenacin treatment of patients >or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial.

Chapple C, DuBeau C, Ebinger U, Rekeda L, Viegas A.

Curr Med Res Opin. 2007 Oct;23(10):2347-58.

PMID:
17706004
14.

Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial.

Staskin D, Sand P, Zinner N, Dmochowski R; Trospium Study Group.

J Urol. 2007 Sep;178(3 Pt 1):978-83; discussion 983-4. Epub 2007 Jul 16.

PMID:
17632131
15.

Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg.

Chapple CR, Fianu-Jonsson A, Indig M, Khullar V, Rosa J, Scarpa RM, Mistry A, Wright DM, Bolodeoku J; STAR study group.

Eur Urol. 2007 Oct;52(4):1195-203. Epub 2007 Jun 6.

PMID:
17574730
16.

The clinical efficacy of tolterodine extended-release is maintained for 24 h in patients with overactive bladder.

Dmochowski R, Kreder K, MacDiarmid S, Carlsson M, Guan Z.

BJU Int. 2007 Jul;100(1):107-10.

17.
18.

Nocturnal polyuria and nocturia relief in patients treated with solifenacin for overactive bladder symptoms.

Brubaker L, FitzGerald MP.

Int Urogynecol J Pelvic Floor Dysfunct. 2007 Jul;18(7):737-41. Epub 2006 Nov 28.

PMID:
17131169
19.

Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.

Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z.

JAMA. 2006 Nov 15;296(19):2319-28. Erratum in: JAMA. 2007 Mar 21:297(11):1195. JAMA. 2007 Oct 24;298(16):1864.

PMID:
17105794
20.

Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder.

Dmochowski R, Abrams P, Marschall-Kehrel D, Wang JT, Guan Z.

Eur Urol. 2007 Apr;51(4):1054-64; discussion 1064. Epub 2006 Oct 20.

PMID:
17097217

Supplemental Content

Support Center